BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu SJ, Enkhzaya S, Lin YY, Tseng TC, Khosbayar T, Tsai CH, Wang TS, Enkhtuya D, Ivshinkhorol D, Naranzul N, Jargalsaikhan B, Amarsanaa J, Baatarkhuu O, Kao JH. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. J Formos Med Assoc 2020;119:712-9. [PMID: 31672433 DOI: 10.1016/j.jfma.2019.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Meshram RJ, Kathwate GH, Gacche RN. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol 2022. [PMID: 35089390 DOI: 10.1007/s00705-022-05375-0] [Reference Citation Analysis]
2 Zulzaga Z, Myagmarsuren E, Woerdenbag HJ, van Puijenbroek EP. Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? J Pharm Policy Pract 2021;14:15. [PMID: 33678195 DOI: 10.1186/s40545-021-00298-8] [Reference Citation Analysis]